Stefan Hartung, chairman of the board of management of Robert Bosch GmbH, at the 2024 Bosch annual press conference next to the Vivalytic analysis platform. Accordingly, Bosch has announced it will be working on a novel BioMEMS technology in medical technology that combines molecular diagnostics with microsystems technology. This enables precise tests for up to 250 genetic characteristics, such as pathogens or genetic mutations, on a single chip – directly at the point of care, such as in a doctor’s office. By 2030, the supplier of technology and services plans to invest around 300 million euros in this with two partners.

Reproduction for press purposes free of charge with credit “Picture: Bosch”.